According to a new research report “T-Cell Immunotherapy – Pipeline Analysis, 2019 - Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, T-cell immunotherapy currently exhibits a proliferating pipeline with 100+ therapeutic candidates.

T-Cell Immunotherapy Pipeline Insights

T-cell immunotherapy consists of T-cell receptor (TCR), tumor-infiltrating lymphocyte (TIL), and chimeric antigen receptor (CAR) T-cell therapy. TCR is an integral membrane protein that is activated by major histocompatibility complex (MHC) molecules in the presence of an antigen. Upon activation, it initiates T-cell response toward the antigen. The activation of TCR is responsible for T-cell proliferation, development, and activation.

TILs refer to the autologous tumor infiltrating lymphocytes that are modified in vitro and re-infiltrate the tumor to initiate apoptosis of the cancer cells.

CAR T-cell therapy is a procedure in which T-cells are collected via apheresis and genetically modified in laboratory by introducing DNA into them. This helps in the development of CAR on the surface of T-cells. The modified T-cells tend to recognize and attack those cells that have the targeted antigen on their surface.
Kymriah (Novartis AG), Yescarta (Kite Pharma Inc.), and Actmera (F. Hoffmann-La Roche Ltd.) are some of the T-cell therapies that have been approved by U.S. Food and Drug Administration (USFDA).

Insights into Pipeline Segments

According to the research findings, majority of T- cell immunotherapies in the pipeline are being developed to be administered by intravenous route. It has been observed that intravenous route of medication is convenient and provides improved patient’s compliance. The administration of therapeutics through intravenous route has shown promising results in clinical studies.

Strategic Advancements Play a Pivotal Role in T-Cell Immunotherapy Development

Companies are actively collaborating in order to speed up the development of new T-cell immunotherapies. For instance, in October 2018, Horizon Discovery Group plc and Celyad SA entered into a collaboration to develop new off-the-shelf CAR T-cell therapies using Horizon’s short hairpin RNA (shRNA) platform. This will be Celyad’s second non-gene-edited donor-derived platform.

Designation Grant by Regulatory Bodies to Accelerate Development Process of T-Cell Immunotherapy

The companies are actively seeking designation grant to accelerate the process of development. For instance, in April 2017, the USFDA granted Breakthrough Therapy Designation to CTL019 (Novartis AG), which is an investigational CAR T-cell therapy for the treatment of adult patients with relapsed and refractory (r/r) diffuse large B-cell lymphoma (DLBCL). Moreover, Celgene Corporation’s bb2121 was granted Breakthrough Therapy Designation by the USFDA for the treatment of patients with r/r multiple myeloma (MM).

Global Market of T-Cell Immunotherapy is Expected to Increase Statistically in the Next 10 years

Currently Kymriah, Yescarta, Keytruda, Durvalumab, and Actmera are some of the marketed drugs. With the emergence of late- and mid-stage pipeline products in the market, the overall T-cell immunotherapy market is expected to grow significantly in the upcoming years.

Novartis AG, Kite Pharma Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Iovance Biotherapeutics Inc., Celgene Corporation, AstraZeneca PLC, Merck & Co. Inc., Bristol-Myers Squibb Company, Pfizer Inc., Mustang Bio Inc., Horizon Discovery Group plc, Celyad SA, and Nanjing Legend Biotechnology Co. Ltd. are some of the key players involved in the development of T-cell immunotherapies.

T-Cell Immunotherapy Pipeline Analysis

• By Phase
• By Molecule Type
• By Route of Administration
• By Company

The report comprises detailed pipeline analysis of T-cell immunotherapies. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the T-cell immunotherapy development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in the report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to T-cell immunotherapy.